Advertisement

Molecular Imaging and Biology

, Volume 16, Issue 6, pp 877–887 | Cite as

Near-Infrared Fluorescence Imaging of Non-Hodgkin’s Lymphoma CD20 Expression Using Cy7-Conjugated Obinutuzumab

  • Xinfeng Lin
  • Hua Zhu
  • Zheng Luo
  • Ye Hong
  • Hong Zhang
  • Xijuan Liu
  • Huirong Ding
  • Huifang Tian
  • Zhi YangEmail author
Research Article

Abstract

Purpose

Obinutuzumab is the first fully humanized and glycoengineered monoclonal antibody (mAb) directly targeting CD20 antigen, which is expressed on B cell lymphocytes and the majority of non-Hodgkin’s lymphoma (NHL). This study aims to design a diagnostic molecular probe, Cy7-Obinutuzumab (Cy7-Obi), in which Cy7 is a near-infrared fluorescent dye. This probe is used to noninvasively image CD20 antigen expressed in NHL cells.

Procedures

Cy7-Obi probe was synthesized through nucleophilic substitution reaction between NHS-Cy7 and obinutuzumab. After purification, the conjugate was fully characterized by a series of methods. The immunoreactivity and molecular specificity of the probe were confirmed using flow cytometry and in vitro microscopy on Raji (CD20-positive) cells. For in vivo imaging, Cy7-Obi probe (1 nmol) was injected intravenously in severe combined immunodeficiency (SCID) mice bearing Raji tumors which overexpress CD20 (n = 3) and was imaged with near-infrared fluorescence (NIRF) at 6, 9, 12, 24, 60, and 96 h post-probe injection. For pre-block, obinutuzumab (3.25 mg) was injected intravenously in tumor-bearing mice 6 h before the administration of Cy7-Obi probe.

Results

The synthesized Cy7-Obi probe in this paper mimics obinutuzumab in both structure and function. Flow cytometry analysis of the probe and obinutuzumab on Raji cells showed minor difference in binding affinity/specificity with CD20. The probe showed significant fluorescence signal when it was examined on Raji cells using in vitro microscopy. The fluorescence signal can be blocked by pretreatment with obinutuzumab. The probe Cy7-Obi also showed high tumor uptake when it was examined by in vivo optical imaging on Raji tumor-bearing mice. The tumor uptake can be blocked by pretreatment with obinutuzumab (n = 3, p < 0.05). The in vivo imaging results were also confirmed by ex vivo imaging of dissected organs. Finally, the probe Cy7-Obi has shown excellent tumor targeting and specificity through immunofluorescence analysis.

Conclusions

We have shown that humanized Cy7-Obi probe can be used for NIRF imaging successfully. The probe may be an effective and noninvasive diagnostic molecular probe capable of tracking CD20 overexpression in NHL.

Key words

Near-infrared fluorescence imaging Cyanine dye indotricarbocyanine CD20 Obinutuzumab Non-Hodgkin’s lymphoma 

Notes

Acknowledgments

We thank the staff in Central Laboratory and Laboratory Animal Unit at Peking University Cancer Hospital & Institute and Dr. Xiaolong Liang in the Department of Biomedical Engineering at the College of Engineering in Peking University for instrumentation support and analysis. This work was supported by the National Natural Science Foundation of China (No. 81071198, No. 81172083, No. 81371592), Beijing Natural Science Foundation (No. 7132040), and Peking University Cancer Hospital& Institute Research Foundation (2013 ZiZhu 12).

Conflict of Interest

The authors declare that they have no conflicts of interest.

Supplementary material

11307_2014_742_MOESM1_ESM.docx (241 kb)
ESM 1 (DOCX 240 kb)

References

  1. 1.
    Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 63:11–30Google Scholar
  2. 2.
    Alexander DD, Mink PJ, Adami HO et al (2007) The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 120:1–39PubMedCrossRefGoogle Scholar
  3. 3.
    Mohrbacher A (2005) B cell non-Hodgkin’s lymphoma: rituximab safety experience. Arthritis Res Ther 7:S19–S25PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Tedder TF, Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15:450–454PubMedCrossRefGoogle Scholar
  5. 5.
    Polyak MJ, Li H, Shariat N, Deans JP (2008) CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem 283:18545–18552PubMedCrossRefGoogle Scholar
  6. 6.
    Kawabata KC, Ehata S, Komuro A et al (2013) TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20. Oncogene 32:2096–2106PubMedCrossRefGoogle Scholar
  7. 7.
    Einfeld DA, Brown JP, Valentine MA et al (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7:711–717PubMedCentralPubMedGoogle Scholar
  8. 8.
    Press OW, Appelbaum F, Ledbetter JA et al (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584–591PubMedGoogle Scholar
  9. 9.
    Anderson KC, Bates MP, Slaughenhoupt BL et al (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:1424–1433PubMedGoogle Scholar
  10. 10.
    Perz J, Topaly J, Fruehauf S et al (2002) Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 43:149–151PubMedCrossRefGoogle Scholar
  11. 11.
    Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 359:613–626PubMedCrossRefGoogle Scholar
  12. 12.
    Robak T (2009) GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 10:588–596PubMedGoogle Scholar
  13. 13.
    Janice MR (2011) Antibody-based therapeutics to watch in 2011. MAbs 3:76–99CrossRefGoogle Scholar
  14. 14.
    Stopar TG, Mlinaric-Rascan I, Fettich J et al (2006) 99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin’s lymphoma imaging agent. Eur J Nucl Med Mol Imaging 33:53–59PubMedCrossRefGoogle Scholar
  15. 15.
    Gmeiner ST, Fettich J, Zver S et al (2008) 99mTc-labelled rituximab, a new non-Hodgkin’s lymphoma imaging agent: first clinical experience. Nucl Med Commun 29:1059–1065CrossRefGoogle Scholar
  16. 16.
    Natarajan A, Gowrishankar G, Nielsen CH et al (2012) Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. Mol Imaging Biol 14:608–616PubMedCrossRefGoogle Scholar
  17. 17.
    Olafsen T, Betting D, Kenanova VE et al (2009) Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med 50:1500–1508PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Olafsen T, Sirk SJ, Betting DJ et al (2010) ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel 23:243–249PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Biffi S, Garrovo C, Macor P et al (2008) In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging 7:272–282PubMedGoogle Scholar
  20. 20.
    Wu Y, Cai W, Chen X (2006) Near-infrared fluorescence imaging of tumor integrin ανβ3 expression with Cy7-labeled RGD. Mol Imaging Biol 8:226–236PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Sampath L, Kwon S, Ke S et al (2007) Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 48:1501–1510PubMedCrossRefGoogle Scholar
  22. 22.
    Kim TI, Park J, Park S et al (2011) Visualization of tyrosinase activity in melanoma cells by a BODIPY-based fluorescent probe. Chem Commun (Camb) 47:12640–12642CrossRefGoogle Scholar
  23. 23.
    Vinegoni C, Botnaru I, Aikawa E et al (2011) Indocyanine green enables near-infrared fluorescence imaging of lipid-rich, inflamed atherosclerotic plaques. Sci Transl Med 3(84):84ra45PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Jensen SA, Day ES, Ko CH et al (2013) Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med 5(209):209ra152PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    van der Poel HG, Buckle T, Brouwer OR et al (2011) Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 60:826–833PubMedCrossRefGoogle Scholar
  26. 26.
    Greg TH (2008) Bioconjugate techniques. In: Greg TH (ed) Fluorescent probes. Academic, San Diego, pp 396–405Google Scholar
  27. 27.
    Morrison LE (2008) Basic principles of fluorescence and energy transfer. Methods Mol Biol 429:3–19PubMedCrossRefGoogle Scholar
  28. 28.
    Marras SA, Kramer FR, Tyagi S (2002) Efficiencies of fluorescence resonance energy transfer and contact-mediated quenching in oligonucleotide probes. Nucleic Acids Res 30:e122PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Miller JN (2005) Fluorescence energy transfer methods in bioanalysis. Analyst 130:265–270PubMedCrossRefGoogle Scholar
  30. 30.
    Brun MP, Gauzy-Lazo L (2013) Protocols for lysine conjugation. Methods Mol Biol 1045:173–187PubMedCrossRefGoogle Scholar
  31. 31.
    Anders JC, Parten BF, Petrie GE et al (2003) Using amino acid analysis to determine absorptivity constants: a validation case study using bovine serum albumin. Biopharm International 16:30–37Google Scholar
  32. 32.
    Van Meerten T, van Rijn RS, Hol S et al (2006) Complement-Induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 12:4027–4035PubMedCrossRefGoogle Scholar
  33. 33.
    Wu L, Wang C, Zhang D et al (2010) Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Cancer Lett 292:208–214PubMedCrossRefGoogle Scholar
  34. 34.
    Aoki V, Sousa JX Jr, Fukumori LM et al (2010) Direct and indirect immunofluorescence. An Bras Dermatol 85:490–500PubMedCrossRefGoogle Scholar
  35. 35.
    Lin X, Zhu H, Hong Y et al (2013) Synthesis and evaluation of Cy7-Rituximab targeting CD20 antigen for in vivo animal fluorescence imaging. Chem J Chinese U 34:2139–2145Google Scholar
  36. 36.
    Natarajan A, Habte F, Liu H et al (2013) Evaluation of 89Zr-rituximab tracer by Cerenkov luminescence imaging and correlation with PET in a humanized transgenic mouse model to image NHL. Mol Imaging Biol 15:468–475PubMedCrossRefGoogle Scholar
  37. 37.
    Tang B, Cui L, Xu K et al (2008) A sensitive and selective near-infrared fluorescent probe for mercuric ions and its biological imaging applications. Chembiochem 9:1159–1164PubMedCrossRefGoogle Scholar
  38. 38.
    Zhang Y, Hong H, Engle JW et al (2012) Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging 2:1–13PubMedCentralPubMedGoogle Scholar
  39. 39.
    Dixit R, Boelsterli UA (2007) Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov Today 12:336–342PubMedCrossRefGoogle Scholar
  40. 40.
    Mashimo T, Takizawa A, Kobayashi J et al (2012) Generation and characterization of severe combined immunodeficiency rats. Cell Rep 2:685–694PubMedCrossRefGoogle Scholar
  41. 41.
    Ghirardelli ML, Jemos V, Gobbi PG (1999) Diagnostic approach to lymph node enlargement. Haematologica 84:242–247PubMedGoogle Scholar

Copyright information

© World Molecular Imaging Society 2014

Authors and Affiliations

  • Xinfeng Lin
    • 1
  • Hua Zhu
    • 1
  • Zheng Luo
    • 1
  • Ye Hong
    • 2
  • Hong Zhang
    • 3
  • Xijuan Liu
    • 3
  • Huirong Ding
    • 3
  • Huifang Tian
    • 3
  • Zhi Yang
    • 1
    Email author
  1. 1.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Nuclear MedicinePeking University Cancer Hospital & InstituteBeijingChina
  2. 2.China Institute of Atomic EnergyBeijingChina
  3. 3.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Central LaboratoryPeking University Cancer Hospital & InstituteBeijingChina

Personalised recommendations